XML 68 R57.htm IDEA: XBRL DOCUMENT
v3.19.1

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands |  |  |  | 8 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Aug. 31, 2018 | Nov. 17, 2017 | Nov. 07, 2017 | Dec. 31, 2017 | Dec. 31, 2018 | Dec. 31, 2017
Rent expense |  |  |  |  | $ 115 | $ 14
Percentage of net profits payments to third party from sale of product |  | 50.00% | 30.00% |  |  |
Credit agreement term |  | 10 years | 10 years |  |  |
Total milestone payments | $ 1,104 |  |  |  |  |
Percentage of right to recoup |  |  |  |  | 35.00% |
Payments for development |  |  |  | $ 3,930 | $ 5,627 |
License Agreement [Member] |  |  |  |  |  |
Agreement term |  |  |  |  | 10 years |
Licensor [Member] |  |  |  |  |  |
Percentage of net profits payments to third party from sale of product |  |  |  |  | 35.00% |
Percentage of right to recoup |  |  |  |  | 60.00% |
Licensor [Member] | Exclusive License and Supply Agreement [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | $ 350 |
Licensor [Member] | Upon FDA Acceptance [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | 1,500 |
Licensor [Member] | Upon FDA Approval [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | 1,000 |
Licensor [Member] | Upon Issuance of Patent Covering [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | 1,500 |
Licensor [Member] | Product Sales [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | 500 |
Licensor [Member] | Calendar Year [Member] |  |  |  |  |  |
Payments for development |  |  |  |  | $ 10,000 |

X
- Definition The agreement is for an initial term. + References No definition available. + Details
Name: | ETON_AgreementTerm
Namespace Prefix: | ETON_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Credit agreement term. + References No definition available. + Details
Name: | ETON_CreditAgreementTerm
Namespace Prefix: | ETON_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total milestone payments. + References No definition available. + Details
Name: | ETON_MilestonePayments
Namespace Prefix: | ETON_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of net profits payments to third party from sale of product. + References No definition available. + Details
Name: | ETON_PercentageOfNetProfitsPaymentsToThirdPartyFromSaleOfProduct
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of right to recoup. + References No definition available. + Details
Name: | ETON_PercentageOfRightToRecoup
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References No definition available. + Details
Name: | us-gaap_LeaseAndRentalExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=ETON_LicensorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_ExclusiveLicenseandSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponFDAAcceptanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponFDAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponIssuanceOfPatentCoveringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_ProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_CalendarYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |